Imugene Limited (IMU.AX)
| Previous close | 0.1250 |
| Open | 0.1300 |
| Bid | 0.1300 x 102397000 |
| Ask | 0.1350 x 716752400 |
| Day's range | 0.1270 - 0.1350 |
| 52-week range | 0.1150 - 0.3150 |
| Volume | |
| Avg. volume | 11,719,153 |
| Market cap | 834.995M |
| Beta (5Y monthly) | 2.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 28 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.53 |
- GlobeNewswire
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates
Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for Biomaterial-Cell Therapy Combination Approach FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” the “Company”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial-based regenerative therapeutics products, announced today
- GlobeNewswire
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic
- GlobeNewswire
Diamond Equity Research Initiates Coverage on Imugene Ltd. (ASX: IMU)
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Imugene Ltd. (ASX: IMU). The in-depth 31-page initiation report includes detailed information on the Imugene’s business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include: Diversified Pipeline with Multiple Candidates in Clinical
